Considerations for Use of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

Dr Naomi Dempsey explains how she decides on an appropriate CDK4/6 inhibitor for patients receiving first-line treatment for metastatic HR+/HER- breast cancer.

Related Keywords

Naomi Dempsey , ,Optimizing Treatment ,Multidisciplinary Approach ,Breast Cancer ,Abc ,Hr Breast Cancer ,Her2 Breast Cancer ,Hr Her2 Breast Cancer ,Her2 Negative Breast Cancer ,Hr Positive Breast Cancer ,Breast Cancer Treatments ,Breast Cancer Therapies ,Multidisciplinary Care ,Medical Oncologists ,Radiation Oncologists ,Surgeons ,Pharmacists ,